NeuroDiscovery AI

NeuroDiscovery AI operates at the intersection of neurological care, clinical-trial technology, real-world evidence, and applied artificial intelligence. Its differentiation is vertical specialization: rather than presenting as a general healthcare analytics vendor, it focuses on neurological disorders and combines longitudinal patient data with imaging, multi-omics, provider workflows, and neurology-specific language models. NeuroTerminal extends that proposition into a platform intended for life sciences and clinical research users, while Patient Matching for Clinical Trials addresses a measurable bottleneck in recruitment. Biomarker Discovery and Real World Evidence Analytics broaden the potential use cases beyond trial enrollment into treatment selection, regulatory support, and therapy adoption. The company states that its network includes more than 540 neurological care providers and that its data covers over 5.2 million patients, although the website analysis cites more than 470 providers, creating a scale discrepancy. Its competitive position therefore depends on validating data breadth, provider access, model performance, and commercial adoption rather than on disclosed funding or market-share metrics.

NeuroDiscovery AI’s trajectory shows a progression from a data-and-AI research proposition toward a packaged commercial platform. Founded in 2023, the company has built around longitudinal neurological records and multimodal inputs, including electronic health records, imaging, and multi-omics data. The May 19, 2026 launch of NeuroTerminal marks the clearest inflection point: patient matching, real-world evidence, provider workflows, and NeuroLLM were brought together under one neurology-focused product. The company also reported ambitions to scale through a potential USD 100 million to USD 150 million financing, but this remains a proposed raise rather than confirmed capital and should not be counted as funding. Organizational development is visible in the leadership roster: Kevin Kozel has served as Chief Commercial Officer since 2023-01, Shruthi Boggram, Jayant Verma, and Garima Bajoria are listed in finance, data science, and chief-of-staff roles from 2024-01, and Vamsi Kasivajjala became CEO in 2025-06. Active hiring and the absence of reported layoffs suggest continued expansion, but employee-count and revenue-growth evidence are limited.